Sucampo Pharmaceuticalsrecently heard back from the FDA regarding its supplemental new drug application for constipation drug Amitiza, which the company is looking to expand into an opioid-induced constipation indication. Aside from laxatives, there is no existing treatment for this indication.
Not surprisingly, the stock surged following word of acceptance from the FDA. This is great news and good timing as well for Sucampo, which has seen increased competition in the broader "constipation market," most notably from the likes of Ironwood Pharmaceuticals. Ironwood's drug Linzess , developed in conjunction with Forest Labs, recently gained FDA approval and will compete directly with Amitiza.
Sucampo's new indication will prove invaluable in helping to offset the increasing competition. Watch the following video for Fool.com analyst Brenton Flynn's full-story coverage.
While you can make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the longterm. In our free report 3 Stocks That Will Help You Retire Rich, we name stocks that could help you build long-term wealth and retire well, and also reveal some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Sucampo Surges in the Wake of the Latest FDA Approval originally appeared on Fool.com.
Brenton Flynn, Dave Williamson, and The Motley Fool hasveno positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.